Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix reported Q1 2026 revenue of $10.8 million, flat year-over-year, but highlighted significant clinical progress for its lead asset AXPAXLI. The Phase 3 SOL-1 trial met its primary superiority endpoint with a p-value of 0.0006, showing that 65.9% of AXPAXLI patients maintained vision at Week 52 compared to 44.2% for aflibercept.
Key figures
- Revenue
- 10785000
- Guidance
- Cash balance sufficient to support planned expenses into 2028; SOL-R topline data expected 1Q 2027; AXPAXLI NDA submission planned based on SOL-1 data
- Revenue Yoy
- 0.8%
- Rd expenses
- 66200000
- Cash balance
- 666700000
- Sol1 primary endpoint p value
- 0.0006
- Sol1 week 52 vision maintenance axpaxli
- 65.9%
- Sol1 week 52 vision maintenance aflibercept
- 44.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.